Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Depreciation and Depletion (2016 - 2017)

Avalo Therapeutics (AVTX) has disclosed Depreciation and Depletion for 4 consecutive years, with $4906.0 as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Depreciation and Depletion fell 23.2% year-over-year to $4906.0, compared with a TTM value of $21956.0 through Dec 2017, down 18.25%, and an annual FY2024 reading of $200000.0, changed 0.0% over the prior year.
  • Depreciation and Depletion was $4906.0 for Q4 2017 at Avalo Therapeutics, down from $5361.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $7881.0 in Q4 2014 and bottomed at $4906.0 in Q4 2017.
  • Average Depreciation and Depletion over 4 years is $6169.3, with a median of $6148.0 recorded in 2015.
  • The sharpest move saw Depreciation and Depletion rose 22.99% in 2016, then fell 23.98% in 2017.
  • Year by year, Depreciation and Depletion stood at $7881.0 in 2014, then fell by 21.99% to $6148.0 in 2015, then rose by 3.9% to $6388.0 in 2016, then dropped by 23.2% to $4906.0 in 2017.
  • Business Quant data shows Depreciation and Depletion for AVTX at $4906.0 in Q4 2017, $5361.0 in Q3 2017, and $5859.0 in Q2 2017.